The landscape for funding psychedelic medicine and its delivery is changing rapidly. While philanthropic funding remains essential, the past several years have seen increasing commercial capital enter the space. This trend is only expected to continue, as major initiatives take flight over the next 12-24 month. How might we work to ensure that financial incentives are aligned with equitable access, and address tensions openly where they exist? What might be some lessons learned from other initiatives that have dealt with similar “growing pains” of scaling?